BeOne Medicines
1,893 posts
BeOne Medicines
@BeOneMedicines
A global oncology company that is discovering and developing innovative treatments for patients worldwide. Cancer has no borders. Neither do we.
- Interested in learning about the advancements BeiGene is making in oncology? #ASCO20
- Our Co-Founder, Chairman and CEO @johnvoyler is speaking on a panel at the @MilkenInstitute Future of Health Summit alongside other healthcare experts @TreedinDC, @pkluetz and @peters_solange. Tune in to the link below at 5:30pm EDT on June 22nd. #MIHealthSummit
- 2023 was a landmark year for our company with significant global growth, data and regulatory milestones and pipeline progress in support of our broader mission to help patients around the world. Learn more about the success and impact we’re having: bit.ly/3JFD59y
- Blood cancer affects millions of people across the globe. BeiGene is committed to improving outcomes for patients by creating impactful medicines that change lives. Learn more about why we do what we do. #BloodCancerAwarenessMonth
- We’re committed to evaluating our BTK inhibitor in a variety of b-cell malignancies with unmet treatment needs. We’re proud to share that more than 3,700 patients have been treated across these trials.
00:00Clinical TrialsFrom beigenemedical.eu - Earlier today, we announced that zanubrutinib achieved superior Progression Free Survival versus ibrutinib in a final analysis of the Phase 3 ALPINE trial in #CLL, as assessed by an independent review committee (IRC) and investigator. bit.ly/3esmA4D
00:00 - In honor of Blood Cancer Awareness Month, we’re sitting down with members of the community to learn what this month means to them. Hear from Ken Johnson, who is living with chronic lymphocytic leukemia. #CLLsm #FightBloodCancer #BCAM #leuksm
- Did you know – with our recent approval in Canada, our internally-developed treatments are now available in China, the U.S., Canada and UAE? Learn more about our pipeline and approach to R&D.
00:00Our PortfolioFrom beonemedicines.com 
00:00- Our Co-Founder, Chairman & CEO @JohnVOyler, who is featured among other global leaders in @MilkenInstitute's Power of Ideas series, calls continued cross-border collaboration crucial in the global fight. #PowerofIdeas
- We are looking forward to discussing results from the interim analysis of the ALPINE trial and other data presented at #EHA2021 during our investor call & webcast later today at 12:00 PM ET. Visit our website to listen in. ir.beigene.com
- After a cancer diagnosis, Ken enrolled in a BeiGene clinical trial with help from his care team. Hear more of Ken’s story as part of the #NaturesBuildingBlocks series produced by @BBCStoryWorks Commercial Productions and presented by @biotechintl
